Author(s): Om Prakash Agrawal*, CK Tyagi, Deenanath Jhade
A novel coronavirus disease (COVID-19), triggered by infection with SARS-CoV-2, has flounced across 31 provinces in China and over 195 countries worldwide. The transition from first symptoms to acute respiratory distress syndrome (ARDS) is extremely probable to be due to unrestrained cytokine release. There is a crucial need to classify safe and active drugs for action. Chloroquine (CQ) exhibitions an inhibitory effect. However, the clinical use of CQ can cause severe side effects. Moreover, hydroxyl-chloroquine (HCQ) also exhibits an antiviral effect highly similar to that of CQ, inhibiting the cytokine storm by suppressing T-cell activation. Coronavirus vaccine will be carry after clinical trials ahead in markets.